Rare Bone Diseases

Rare Bone Diseases is a Fellows Training Series module featuring a series of lectures from Sky Graybill, MD and questions to test your knowledge. 

Course Outline
  • Paget's Disease of the Bone
  • Osteogenesis Imperfecta
  • McCune-Albright Syndrome
  • Hypophosphatemia
  • Hypophosphatasia
  • Albright Hereditary Osteodystrophy

 

Learning Objectives

Upon completing this activity, learners will better be able to:

  • Assess who is at risk for different rare bone diseases 
  • Diagnosis bone disease
  • Manage bone disease in a patient 

Additional Information

Target Audience: 
Fellow
Educator/Teacher
Competency Area: 
Medical Knowledge
Topic Area: 
Bone and Calciotropic Hormones
Growth Disorders
Level of Outcomes: 
Level 1 (Participation)
Activity summary
Available credit: 
  • 1.50 ABIM MOC
  • 1.50 AMA PRA Category 1 Credits
  • 1.50 CME Certificate of Participation
Course opens: 
01/31/2020
Course expires: 
01/31/2023
Rating: 
0

Faculty

Sky Graybill, MD
Brook Army Medical Center

STATEMENT OF INDEPENDENCE

As a provider of CME accredited by the Accreditation Council for Continuing Medical Education, the Endocrine Society has a policy of ensuring that the content and quality of this educational activity are balanced, independent, objective, and scientifically rigorous. The scientific content of this activity was developed under the supervision of the Endocrine Society’s guideline task force.

DISCLOSURE POLICY

The faculty, committee members, and staff who are in position to control the content of this activity are required to disclose to the Endocrine Society and to learners any relevant financial relationship(s) of the individual or spouse/partner that have occurred within the last 12 months with any commercial interest(s) whose products or services are related to the content. Financial relationships are defined by remuneration in any amount from the commercial interest(s) in the form of grants; research support; consulting fees; salary; ownership interest (e.g., stocks, stock options, or ownership interest excluding diversified mutual funds); honoraria or other payments for participation in speakers' bureaus, advisory boards, or boards of directors; or other financial benefits. The intent of this disclosure is not to prevent planners with relevant financial relationships from planning or delivery of content, but rather to provide learners with information that allows them to make their own judgments of whether these financial relationships may have influenced the educational activity with regard to exposition or conclusion. The Endocrine Society has reviewed all disclosures and resolved or managed all identified conflicts of interest, as applicable.

The following faculty reported relevant financial relationships:

Sky Graybill, MD: US Military 

Endocrine Society staff associated with the development of content for this activity reported no relevant financial relationships.

DISCLAIMERS

USE OF PROFESSIONAL JUDGMENT:

The educational content in this activity relates to basic principles of diagnosis and therapy and does not substitute for individual patient assessment based on the health care provider’s examination of the patient and consideration of laboratory data and other factors unique to the patient. Standards in medicine change as new data become available.

DRUGS AND DOSAGES:

When prescribing medications, the physician is advised to check the product information sheet accompanying each drug to verify conditions of use and to identify any changes in drug dosage schedule or contraindications.

POLICY ON UNLABELED/OFF-LABEL USE

The Endocrine Society has determined that disclosure of unlabeled/off-label or investigational use of commercial product(s) is informative for audiences and therefore requires this information to be disclosed to the learners at the beginning of the presentation. Uses of specific therapeutic agents, devices, and other products discussed in this educational activity may not be the same as those indicated in product labeling approved by the Food and Drug Administration (FDA). The Endocrine Society requires that any discussions of such “off-label” use be based on scientific research that conforms to generally accepted standards of experimental design, data collection, and data analysis. Before recommending or prescribing any therapeutic agent or device, learners should review the complete prescribing information, including indications, contraindications, warnings, precautions, and adverse events.

PRIVACY AND CONFIDENTIALITY STATEMENT

The Endocrine Society will record learner’s personal information as provided on CME evaluations to allow for issuance and tracking of CME certificates. The Endocrine Society may also track aggregate responses to questions in activities and evaluations and use these data to inform the ongoing evaluation and improvement of its CME program. No individual performance data or any other personal information collected from evaluations will be shared with third parties.

ACKNOWLEDGMENT OF COMMERCIAL SUPPORT

This educational activity is supported by an independent medical educational grant from Ultragenyx Pharmaceutical.

Accreditation Statement

The Endocrine Society is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The Endocrine Society has achieved Accreditation with Commendation.

The Endocrine Society designates this enduring material for a maximum of 1.5 AMA PRA Category 1 Credits. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
 

Maintenance of Certification

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.5 MOC points in the American Board of Internal Medicine’s (ABIM) and American Board of Pediatric's Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM and ABP MOC credit.

Available Credit

  • 1.50 ABIM MOC
  • 1.50 AMA PRA Category 1 Credits
  • 1.50 CME Certificate of Participation

Accreditation Period

Course opens: 
01/31/2020
Course expires: 
01/31/2023

To participate in this activity you must be enrolled in a fellowship program participating with the Fellows Training Series, and a program administrator must add you to this course. If your program participates, please contact your program director or coordinator to add you to this course.

If you are interested in learning more about Fellows Training Series, please contact mgraham@endocrine.org